Inclusion Criteria:

1. Patients must have histologically proven breast cancer with metastatic disease to the
brain.

2. Patients must have measurable disease on MRI that has progressed after prior therapy.
PD will be defined as a >/=25% increase in the sum of the products of greatest
perpendicular diameters of index measurable lesion(s) on Gd-MRI, the appearance of
new lesions on scan, or clinical or neurologic worsening despite stable disease on
the last 2 scans.

3. Patients may have had any number of prior surgeries, radiation and/or chemotherapy
regimens as adjuvant, neoadjuvant or palliative therapy for the treatment of their
disease

4. Patients must be >/=18 years of age.

5. Patients must have an ECOG performance status of 0,1 or 2.

6. Patients must have adequate bone marrow function as evidenced by an absolute
neutrophil count >/=1,500/microliters and a platelet count >/=100,000/microliter,
adequate renal function as evidenced by serum creatinine hepatic function as evidenced by serum total bilirubin ALT/SGPT
7. Patients must have recovered and healed from the effects of any prior surgery, must
have received prior chemotherapy at least 2 weeks prior to dosing with adequate
recovery of WBC and platelet counts, and at least 12 weeks must have elapsed from the
completion of radiotherapy, unless there are new lesions appearing on imaging within
this 12 weeks frame.

8. Women of child-bearing potential (i.e. within the past 12 months, if > 50 years of age. If in doubt, check FSH, LH and
estradiol level) must have a negative urine or serum pregnancy test at screening.

9. Sexually active patients must agree to use adequate contraception (abstinence or
barrier contraceptives must be used throughout the trial and one month after end of
treatment) for the duration of the study .

10. Patients or their legal representative must be able to read, understand and sign an
informed consent form (ICF).

11. TPI 287 may interfere with coumadin dosing and patients who are taking this
combination will require monitoring of their PT, PTT and INR.

Exclusion Criteria:

1. Patients who are receiving concurrent enzyme-inducing anti-epileptic drugs (EIAEDs)
(e.g., carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital and
primidone) or who received EIAEDs within 2 weeks prior to the first dose of study
drug.

2. Patients with uncontrolled intracranial hypertension syndrome (defined as:
persistence of headache, transient visual obscurations, and/or diplopia despite
optimal clinical management) or uncontrolled seizure activity (i.e. recorded despite
optimal medical management).

3. Patients who are not on a stable or decreasing steroid dose for the previous week
prior to the first dose of study enrollment

4. Patients with an active infection (i.e., clinical signs or symptoms, including, but
not limited to: bleeding/pustulant skin infections; productive cough associated with
fever) on antibiotics or with a fever >/=38.5°C within 3 days prior to registration
(i.e. date when the patient signs the consent and/or the patient is registered in
CORE).

5. Patients who are taking bevacizumab or have taken bevacizumab within the past 2 weeks
for treatment of their brain metastases

6. Patients with NYHA Class 3 or 4 congestive heart failure.

7. Patients with known HIV or Hepatitis B or C

8. Patients who are pregnant or lactating or not practicing adequate contraception

9. Patients with any other medical condition, including mental illness or substance
abuse, deemed by the Investigator to be likely to interfere with the patient's
ability to sign the ICF or his/her ability to cooperate and participate in the study,
or to interfere with the interpretation of the results.

10. Patients who are receiving concomitant systemic therapy for breast cancer.

11. Patients with leptomeningeal disease (LMD) or with a history of LMD will be excluded.